Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edoxaban - Daiichi Sankyo Company

Next Previous
Drug Profile

Edoxaban - Daiichi Sankyo Company

Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Lixiana OD; Roteas; SAVAYSA

Latest Information Update: 20 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Kyushu University
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • Phase III Pulmonary hypertension
  • No development reported Venous thrombosis

Most Recent Events

  • 09 Dec 2024 Development is still ongoing for phase III trial in Venous thromboembolism (In children, In infants, In neonates) in Argentina, Netherlands, Romania, Thailand, Guatemala and Bulgaria (PO, Suspension) (NCT02798471), (Daiichi Sankyo website, December 2024)
  • 03 Dec 2024 Development is still ongoing for phase III trial in Venous thromboembolism (In children, In adolescents) in India, Netherlands, Romania, Chile, Norway, Thailand, Panama, Taiwan, Argentina and El Salvador (PO, Tablet), (Daiichi Sankyo website, December 2024)
  • 25 Dec 2023 Updated efficacy data from the phase III ELDERCARE-AF trial in Atrial fibrillation presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top